Pfizer Inc. $PFE Shares Purchased by Focus Partners Advisor Solutions LLC

Focus Partners Advisor Solutions LLC lifted its holdings in Pfizer Inc. (NYSE:PFE) by 26.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 197,668 shares of the biopharmaceutical company’s stock after acquiring an additional 41,885 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Pfizer were worth $4,922,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Everett Harris & Co. CA grew its position in Pfizer by 0.5% during the fourth quarter. Everett Harris & Co. CA now owns 269,665 shares of the biopharmaceutical company’s stock valued at $6,715,000 after buying an additional 1,285 shares during the period. Gordian Capital Singapore Pte Ltd acquired a new stake in Pfizer during the fourth quarter valued at $100,000. Waddell & Associates LLC grew its position in Pfizer by 6.3% during the fourth quarter. Waddell & Associates LLC now owns 25,810 shares of the biopharmaceutical company’s stock valued at $643,000 after buying an additional 1,532 shares during the period. Claret Asset Management Corp grew its position in Pfizer by 0.7% during the fourth quarter. Claret Asset Management Corp now owns 285,970 shares of the biopharmaceutical company’s stock valued at $7,121,000 after buying an additional 1,993 shares during the period. Finally, Cerity Partners LLC grew its position in Pfizer by 83.3% during the fourth quarter. Cerity Partners LLC now owns 3,187,455 shares of the biopharmaceutical company’s stock valued at $79,368,000 after buying an additional 1,448,806 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Citigroup raised their price target on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. CICC Research started coverage on shares of Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective on the stock. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating in a report on Tuesday. Finally, HSBC increased their price objective on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $28.82.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved an expanded indication for HYMPAVZI, broadening use to more hemophilia A/B patients and children, which could increase future sales. Article Title
• Positive Sentiment: Pfizer’s obesity pipeline remains in focus after phase 2b data showed about 16% weight loss, reinforcing optimism that the company may build a meaningful next-generation growth franchise. Article Title
• Neutral Sentiment: BMO Capital kept its Buy rating on Pfizer, adding support for the stock but not changing the core story by itself. Article Title
• Neutral Sentiment: Multiple articles highlighted Pfizer’s obesity strategy and its effort to find new growth after the COVID windfall faded, which is encouraging but still early-stage. Article Title
• Negative Sentiment: Broader commentary on patent cliffs and rising competition in obesity drugs underscores the pressure Pfizer faces to replace lost revenue and prove its pipeline can deliver. Article Title

Pfizer Stock Up 0.2%

Shares of NYSE PFE opened at $25.67 on Wednesday. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The stock has a market cap of $146.28 billion, a PE ratio of 19.59 and a beta of 0.34. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The company has a 50-day moving average of $26.56 and a 200 day moving average of $26.31.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter in the prior year, the company earned $0.92 EPS. Pfizer’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio is currently 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.